February 2025's Top Asian Growth Companies With High Insider Ownership

As global markets navigate the complexities of geopolitical tensions and evolving trade policies, Asia's stock markets have shown resilience, with China's indices buoyed by strong performances in the technology sector. In this climate, growth companies with high insider ownership can offer unique insights into investor confidence and strategic alignment, making them compelling considerations for those analyzing market opportunities.

Top 10 Growth Companies With High Insider Ownership In Asia

Name

Insider Ownership

Earnings Growth

Seojin SystemLtd (KOSDAQ:A178320)

32.1%

39.9%

Sineng ElectricLtd (SZSE:300827)

36.3%

41.4%

Suzhou Sunmun Technology (SZSE:300522)

35.4%

92.8%

Laopu Gold (SEHK:6181)

36.4%

43.2%

Anhui Huaheng Biotechnology (SHSE:688639)

32.9%

53.5%

UTour Group (SZSE:002707)

24.1%

32.8%

Bioneer (KOSDAQ:A064550)

15.9%

104.8%

HANA Micron (KOSDAQ:A067310)

18.3%

119.4%

Oscotec (KOSDAQ:A039200)

21.2%

132.4%

Fulin Precision (SZSE:300432)

13.6%

71%

Click here to see the full list of 640 stocks from our Fast Growing Asian Companies With High Insider Ownership screener.

Here we highlight a subset of our preferred stocks from the screener.

ALTEOGEN

Simply Wall St Growth Rating: ★★★★★★

Overview: ALTEOGEN Inc. is a biotechnology company that specializes in developing long-acting biobetters, proprietary antibody-drug conjugates, and antibody biosimilars, with a market cap of approximately ₩21.40 trillion.

Operations: The company's revenue is primarily derived from its biotechnology segment, totaling approximately ₩74.38 billion.

Insider Ownership: 25.9%

Return On Equity Forecast: 68% (2027 estimate)

ALTEOGEN, with significant insider ownership, is poised for substantial growth. Its revenue is projected to surge 84.2% annually, outpacing the Korean market's average. The company anticipates becoming profitable within three years with a robust earnings growth forecast of 140.63% per year and an impressive return on equity predicted at 67.6%. Recent private placements raised approximately KRW 155 billion, indicating strong institutional interest and support from prominent investment trusts and securities firms in Asia.

KOSDAQ:A196170 Ownership Breakdown as at Feb 2025
KOSDAQ:A196170 Ownership Breakdown as at Feb 2025

Suzhou Zelgen BiopharmaceuticalsLtd

Simply Wall St Growth Rating: ★★★★★★

Overview: Suzhou Zelgen Biopharmaceuticals Co., Ltd. is a company focused on the research, development, and commercialization of innovative pharmaceuticals, with a market cap of CN¥22.01 billion.